Status:
ACTIVE_NOT_RECRUITING
Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis
Lead Sponsor:
Uppsala University
Collaborating Sponsors:
Karolinska Institutet
Conditions:
Mastocytosis, Systemic
Eligibility:
All Genders
18+ years
Brief Summary
Systemic Mastocytosis is a rare and complex disease caused by accumulation of mast cells. The skin, bones, gastrointestinal tract, bone marrow and liver are the organs most often affected. Symptoms ca...
Detailed Description
Systemic Mastocytosis (SM) is a rare and complex disease caused by accumulation of mast cells leading to release of mediator substances (e.g., cytokines, prostaglandins, histamine and tryptase). The s...
Eligibility Criteria
Inclusion
- Swedish-speaking individuals aged 18 years or older and diagnosed with indolent systemic mastocytosis (ISM) or advanced systemic mastocytosis (AdvSM), verified by a bone marrow biopsy
Exclusion
- An assessment by the treating physician that the individual has a cognitive impairment making participation impossible
- The patient has undergone an allogeneic stem cell transplant
Key Trial Info
Start Date :
March 25 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 15 2028
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06065007
Start Date
March 25 2024
End Date
November 15 2028
Last Update
April 4 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska Institutet
Stockholm, Sweden
2
Uppsala University
Uppsala, Sweden